Better, Safer Prostate Biopsy™
“Like all cancers, screening is key and early detection makes a difference. PrecisionPoint® can provide better and earlier detection of prostate cancer, allowing patients to start treatment sooner and improve their outcomes.”
Dr. Matthew Allaway, Founder, Perineologic®
“Like all cancers, screening is key and early detection makes a difference. PrecisionPoint® can provide better and earlier detection of prostate cancer, allowing patients to start treatment sooner and improve their outcomes.”
Dr. Matthew Allaway, Founder, Perineologic®
Now there is a better option…
BENEFITS of OUR Approach
Improved Cancer Detection
No Bowel Prep
Speedy Recovery
Made In The USA
BENEFITS of OUR Approach
Improved Cancer Detection
No Bowel Prep
Speedy Recovery
Made In The USA
“I tell everyone I know who needs a biopsy: You don’t want the transrectal biopsy, you want the best that is available. With the PrecisionPoint®, my doctor was able to find the cancer.”
“I tell everyone I know who needs a biopsy: You don’t want the transrectal biopsy, you want the best that is available. With the PrecisionPoint®, my doctor was able to find the cancer.”
What Is PrecisionPoint®?
The PrecisionPoint® Transperineal Access System (PPTAS) is the first FDA cleared device allowing free-handed transperineal biopsy of the prostate. The device and technique eliminate the need for bowel prep and antibiotics prior to the prostate biopsy.
The procedure allows access to the prostate through the perineum or “taint”, avoiding the rectum completely. The procedure takes 15-20 minutes and can be performed under local or twilight anesthesia.
A recent study published in the British Journal of Urology found that 94% of missed cancers after transrectal prostate biopsies were located in the anterior region of the prostate. The PrecisionPoint® Transperineal Access System allows strategic sampling of the anterior portion of the prostate where these missed cancers have been found.
At Perineologic® , we understand your concern about the possibility of having prostate cancer. Your urologist is trained to perform a better, safer prostate biopsy using the PrecisionPoint® Transperineal Access System.
What Is PrecisionPoint®?
The PrecisionPoint® Transperineal Access System (PPTAS) is the first FDA cleared device allowing free-handed transperineal biopsy of the prostate. The device and technique eliminate the need for bowel prep and antibiotics prior to the prostate biopsy.
The procedure allows access to the prostate through the perineum or “taint”, avoiding the rectum completely. The procedure takes 15-20 minutes and can be performed under local or twilight anesthesia.
A recent study published in the British Journal of Urology found that 94% of missed cancers after transrectal prostate biopsies were located in the anterior region of the prostate. The PrecisionPoint® Transperineal Access System allows strategic sampling of the anterior portion of the prostate where these missed cancers have been found.
At Perineologic® , we understand your concern about the possibility of having prostate cancer. Your urologist is trained to perform a better, safer prostate biopsy using the PrecisionPoint® Transperineal Access System.
PrecisionPoint® is Revolutionizing Prostate Biopsy…
Due to its safety and effectiveness, this state-of-the-art approach is being rapidly adopted around the world.
PrecisionPoint® Procedures Performed Worldwide
Have a Question? Contact Us!
Thank you for your interest in Perineologic®!
Other Ways to Contact Us
(240) 727-7662
Perineologic®
183 N. Centre Street
Cumberland, MD 21502
United States
MEDIA CENTER : PrecisionPoint® and Related Topics
MEDIA CENTER : PrecisionPoint® and Related Topics
14
SEP2022FOX 45
Morning News
In this video, Rick Bartlett, a prostate cancer survivor, discusses how early detection and a new procedure ensured that he was able to spend more years with his family.
15
JUN2022Prostate Cancer
Foundation
In this video by the Prostate Cancer Foundation, medical oncologist Dr. Matthew Rettig shares three tips to help prevent and manage prostate cancer.
23
MAY2022Med Device
Online
Dr. Matthew Allaway discusses important lessons learned throughout the development process of the PrecisionPoint™ Transperineal Access System.
17
MAY2022ZERO
Cancer
Explore ZERO Cancer’s extensive peer support program.
09
MAY2022European Society
of Radiology
Researchers provide a framework and guide for urologists interested in adopting the transperineal approach to prostate biopsy under local anesthesia.
18
APR2022PCF
News
The ZERO Cancer annual Run/Walk series is returning to an in-person event this year!
